Background: False-positive mammography results are common. Biennial screening may decrease the cumulative probability of false-positive results across many years of repeated screening but could also delay cancer diagnosis.
Objective: To compare the cumulative probability of false-positive results and the stage distribution of incident breast cancer after 10 years of annual or biennial screening mammography.
Design: Prospective cohort study.
Setting: 7 mammography registries in the National Cancer Institute-funded Breast Cancer Surveillance Consortium.
Participants: 169,456 women who underwent first screening mammography at age 40 to 59 years between 1994 and 2006 and 4492 women with incident invasive breast cancer diagnosed between 1996 and 2006.
Measurements: False-positive recalls and biopsy recommendations stage distribution of incident breast cancer.
Results: False-positive recall probability was 16.3% at first and 9.6% at subsequent mammography. Probability of false-positive biopsy recommendation was 2.5% at first and 1.0% at subsequent examinations. Availability of comparison mammograms halved the odds of a false-positive recall (adjusted odds ratio, 0.50 [95% CI, 0.45 to 0.56]). When screening began at age 40 years, the cumulative probability of a woman receiving at least 1 false-positive recall after 10 years was 61.3% (CI, 59.4% to 63.1%) with annual and 41.6% (CI, 40.6% to 42.5%) with biennial screening. Cumulative probability of false-positive biopsy recommendation was 7.0% (CI, 6.1% to 7.8%) with annual and 4.8% (CI, 4.4% to 5.2%) with biennial screening. Estimates were similar when screening began at age 50 years. A non-statistically significant increase in the proportion of late-stage cancers was observed with biennial compared with annual screening (absolute increases, 3.3 percentage points [CI, -1.1 to 7.8 percentage points] for women age 40 to 49 years and 2.3 percentage points [CI, -1.0 to 5.7 percentage points] for women age 50 to 59 years) among women with incident breast cancer.
Limitations: Few women underwent screening over the entire 10-year period. Radiologist characteristics influence recall rates and were unavailable. Most mammograms were film rather than digital. Incident cancer was analyzed in a small sample of women who developed cancer.
Conclusion: After 10 years of annual screening, more than half of women will receive at least 1 false-positive recall, and 7% to 9% will receive a false-positive biopsy recommendation. Biennial screening appears to reduce the cumulative probability of false-positive results after 10 years but may be associated with a small absolute increase in the probability of late-stage cancer diagnosis.
Primary funding source: National Cancer Institute.
Mammographic screening interval in relation to tumor characteristics and false-positive risk by race/ethnicity and age.Cancer. 2013 Nov 15;119(22):3959-67. doi: 10.1002/cncr.28310. Epub 2013 Aug 26. Cancer. 2013. PMID: 24037812 Free PMC article.
Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy.JAMA Intern Med. 2013 May 13;173(9):807-16. doi: 10.1001/jamainternmed.2013.307. JAMA Intern Med. 2013. PMID: 23552817 Free PMC article.
Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates?J Natl Cancer Inst. 2013 Mar 6;105(5):334-41. doi: 10.1093/jnci/djs645. Epub 2013 Feb 5. J Natl Cancer Inst. 2013. PMID: 23385442 Free PMC article. Clinical Trial.
Benefits and Harms of Breast Cancer Screening: A Systematic Review.JAMA. 2015 Oct 20;314(15):1615-34. doi: 10.1001/jama.2015.13183. JAMA. 2015. PMID: 26501537 Review.
Screening for Breast Cancer: A Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jan. Report No.: 14-05201-EF-1. Agency for Healthcare Research and Quality (US). 2016. PMID: 26889531 Free Books & Documents. Review.
Cited by 115 articles
Developing global image feature analysis models to predict cancer risk and prognosis.Version 2. Vis Comput Ind Biomed Art. 2019;2(1):17. doi: 10.1186/s42492-019-0026-5. Epub 2019 Nov 19. Vis Comput Ind Biomed Art. 2019. PMID: 32190407 Free PMC article.
Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer.Int J Cancer. 2020 Jun 15;146(12):3485-3494. doi: 10.1002/ijc.32815. Epub 2019 Dec 16. Int J Cancer. 2020. PMID: 31785151 Free PMC article.
A Circulating miRNA Signature for Stratification of Breast Lesions among Women with Abnormal Screening Mammograms.Cancers (Basel). 2019 Nov 26;11(12):1872. doi: 10.3390/cancers11121872. Cancers (Basel). 2019. PMID: 31769433 Free PMC article.
Development and Assessment of a New Global Mammographic Image Feature Analysis Scheme to Predict Likelihood of Malignant Cases.IEEE Trans Med Imaging. 2020 Apr;39(4):1235-1244. doi: 10.1109/TMI.2019.2946490. Epub 2019 Oct 9. IEEE Trans Med Imaging. 2020. PMID: 31603818
Extraordinary Claims Don't always Require Extraordinary Evidence, but They Do Require Good Quality Evidence.Asian Pac J Cancer Prev. 2019 Jul 1;20(7):1935-1937. doi: 10.31557/APJCP.2019.20.7.1935. Asian Pac J Cancer Prev. 2019. PMID: 31350947 Free PMC article. No abstract available.
- U01 CA063740/CA/NCI NIH HHS/United States
- R03CA150007/CA/NCI NIH HHS/United States
- U01CA70040/CA/NCI NIH HHS/United States
- U01CA63740/CA/NCI NIH HHS/United States
- U01 CA063736-10/CA/NCI NIH HHS/United States
- U01 CA070040-10/CA/NCI NIH HHS/United States
- U01CA69976/CA/NCI NIH HHS/United States
- U01 CA070040/CA/NCI NIH HHS/United States
- RC2CA148577/CA/NCI NIH HHS/United States
- U01CA70013/CA/NCI NIH HHS/United States
- U01 CA086082/CA/NCI NIH HHS/United States
- U01 CA063731/CA/NCI NIH HHS/United States
- U01 CA086076/CA/NCI NIH HHS/United States
- R03 CA150007/CA/NCI NIH HHS/United States
- RC2 CA148577/CA/NCI NIH HHS/United States
- U01CA63736/CA/NCI NIH HHS/United States
- U01CA86082/CA/NCI NIH HHS/United States
- U01 CA069976/CA/NCI NIH HHS/United States
- U01CA86076/CA/NCI NIH HHS/United States
- U01 CA063736/CA/NCI NIH HHS/United States
- U01 CA086082-10/CA/NCI NIH HHS/United States
- U01 CA063731-10/CA/NCI NIH HHS/United States
- U01 CA069976-10/CA/NCI NIH HHS/United States
- RC2 CA148577-01/CA/NCI NIH HHS/United States
- U01 CA086076-10/CA/NCI NIH HHS/United States
- U01 CA063740-11/CA/NCI NIH HHS/United States
- U01 CA070013-10/CA/NCI NIH HHS/United States
- U01 CA070013/CA/NCI NIH HHS/United States
- U01CA63731/CA/NCI NIH HHS/United States
- R03 CA150007-01/CA/NCI NIH HHS/United States